Ace inhibitors
Reading File
Finding Sources
Searching PubMed
"ACE inhibitors" AND "cardiovascular outcomes"
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Now I have comprehensive information from multiple authoritative textbooks. Let me compile the full response.
ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)
Mechanism of Action
ACE inhibitors block the enzyme that converts the inactive decapeptide angiotensin I to the active octapeptide angiotensin II. The same enzyme (also called kinase II) also degrades bradykinin, so ACE inhibitors simultaneously:
- Prevent angiotensin II formation
- Accumulate bradykinin
In heart failure, excessive angiotensin II acts via the AT1 receptor to cause:
- Vasoconstriction (increases ventricular afterload)
- Maladaptive LV remodeling (myocyte hypertrophy, extracellular matrix expansion)
- Sympathetic nervous system activation
- Prothrombotic effects
- Aldosterone release → sodium retention and volume expansion
- Arginine vasopressin (ADH) release
By blocking all of these, ACE inhibitors reduce preload and afterload, improve cardiac output, and exert renal and cardioprotective effects.
(Goldman-Cecil Medicine, Barash Clinical Anesthesia 9e)
Available Drugs
ACE inhibitors differ in potency, duration of action, and whether they are prodrugs requiring hepatic esterase conversion (e.g., enalapril, quinapril, ramipril). Notable agents:
| Drug | Brand | Notes |
|---|---|---|
| Captopril | Generic | First ACE inhibitor; more side effects/drug interactions; TID dosing |
| Enalapril | Vasotec | Only IV formulation available (enalaprilat); prodrug |
| Lisinopril | Prinivil, Zestril | Not a prodrug; long half-life; once-daily dosing |
| Ramipril | Altace | Prodrug; well-studied post-MI |
| Quinapril | Accupril | Prodrug |
| Fosinopril | Generic | Dual hepatic/renal elimination |
| Benazepril | Lotensin | - |
| Moexipril | Generic | - |
| Perindopril | Generic | - |
| Trandolapril | Generic | - |
(Lippincott Illustrated Reviews Pharmacology; Barash Clinical Anesthesia 9e)
Clinical Indications
- Hypertension - Reduces arterial pressure through arteriolar vasodilation; cardiac output unchanged or modestly increased; no orthostatic hypotension (baroreceptors intact)
- Heart failure with reduced ejection fraction (HFrEF) - First-line alongside beta-blockers, MRAs, and SGLT2 inhibitors for NYHA class II-IV; also beneficial in asymptomatic LV dysfunction (NYHA class I)
- Post-myocardial infarction - Especially in patients with diabetes, hypertension, or LV dysfunction; reduces MI incidence, sudden cardiac death, and hospitalization
- Diabetic nephropathy / CKD - Renal protective: reduces efferent arteriolar resistance, normalizes glomerular capillary pressure, slows progression of proteinuric nephropathy
- High cardiovascular risk - Substantially decreased MI, stroke, and mortality in patients with vascular disease or diabetes at high risk
Note: ACE inhibitors did not substantially improve outcomes in HFpEF (preserved ejection fraction) in major RCTs.
(Goldman-Cecil Medicine; Barash Clinical Anesthesia 9e)
Heart Failure Dosing (Target Doses)
| Drug | Starting Dose | Target Dose |
|---|---|---|
| Captopril | 6.25 mg TID | 50 mg TID |
| Enalapril | 2.5 mg BID | 10-20 mg BID |
| Lisinopril | 2.5-5 mg OD | 20-35 mg OD |
| Ramipril | 2.5 mg OD | 5 mg BID or 10 mg OD |
| Trandolapril | 0.5 mg OD | 4 mg OD |
(Goldman-Cecil Medicine)
Hemodynamic Effects
- Decrease LV afterload
- Improve arterial compliance
- Reduce arterial pressure
- Enhance cardiac output
- Increase renal blood flow
- Facilitate natriuresis
- Reduce chronically elevated sympathetic tone
- Do not cause orthostatic hypotension (baroreflexes intact) unless the patient is hypovolemic from diuretics or is on other vasodilators
(Barash Clinical Anesthesia 9e)
Side Effects
| Side Effect | Details |
|---|---|
| Dry cough | Most common; affects up to 20% of patients; due to bradykinin accumulation in the lungs; resolves on stopping the drug |
| Angioedema | Rare but life-threatening (0.1-0.5%); edema of lips, tongue, glottis - can compromise airway; 5x more common in those of African ancestry; usually occurs with initial dose(s) |
| Hyperkalemia | Risk in CKD, or when combined with K+-sparing diuretics (spironolactone, triamterene) or K+ supplements |
| Acute renal failure | Especially in bilateral renal artery stenosis (precipitous drop in GFR when efferent tone removed) |
| Hypotension | "First-dose effect" particularly in elderly; start low-dose in office setting |
| Teratogenicity | Contraindicated in pregnancy (especially 2nd/3rd trimester - fetal renal hypoperfusion) |
| Neutropenia | Reversible; rare |
| Taste disturbance | Especially with captopril |
| Blunts hypokalemia | ACE inhibitors blunt the hypokalemic effects of thiazide and loop diuretics (useful side effect) |
(Barash Clinical Anesthesia 9e; Goodman & Gilman's; Harrison's Principles)
Contraindications
- History of angioedema (absolute)
- Bilateral renal artery stenosis (risk of acute renal failure)
- Pregnancy (fetotoxic - renal tubular dysgenesis, oligohydramnios)
- Combination with ARB-neprilysin inhibitor (sacubitril/valsartan) - risk of angioedema is high; contraindicated
- Symptomatic hypotension (SBP < 90 mmHg)
Cautions and Drug Interactions
- Significant hyperkalemia (K+ > 5.0 mmol/L) - use with caution
- Significant renal dysfunction (creatinine ≥ 2.5 mg/dL) - specialist advice
- NSAIDs - attenuate antihypertensive effect of ACE inhibitors; may worsen renal function
- K+-sparing diuretics and MRAs (spironolactone, eplerenone) - hyperkalemia risk
- ACE inhibitor + ARB combination - contraindicated (no extra efficacy; increased side effects including renal dysfunction and hyperkalemia)
- "Low-salt" substitutes - often high in K+; risk of hyperkalemia
(Goldman-Cecil Medicine; Barash Clinical Anesthesia 9e)
ACE Inhibitors vs. ARBs
| Feature | ACE Inhibitor | ARB |
|---|---|---|
| Mechanism | Blocks ACE enzyme | Blocks AT1 receptor directly |
| Bradykinin accumulation | Yes | Modest (via AT2 receptor) |
| Cough | Yes (up to 20%) | No |
| Angioedema | Yes (0.1-0.5%) | Rare (lower rate) |
| Efficacy in HFrEF | Proven | Similar (use as substitute if ACEI not tolerated) |
| Preferred modern option | ARNI (sacubitril/valsartan) preferred over either | Same |
When a patient develops cough or angioedema on an ACE inhibitor, switch to an ARB. For HFrEF, the preferred modern approach is an ARNI (sacubitril/valsartan) rather than a standalone ACE inhibitor or ARB, started as early as possible in the treatment course.
(Goldman-Cecil Medicine; Goodman & Gilman's Pharmacological Basis of Therapeutics)
Which is the best tolerated
Finding Sources
Searching PubMed
"ACE inhibitors" AND tolerability AND comparison
Finding Sources
Finding Sources
Reading File
Reading File
Here is a focused answer on tolerability across ACE inhibitors:
Best-Tolerated ACE Inhibitor
There is no single "best tolerated" ACE inhibitor for every patient, but newer agents (lisinopril, ramipril, enalapril, perindopril) are consistently better tolerated than captopril, which was the first of the class.
Why Captopril is the Least Tolerated
Captopril contains a sulfhydryl (thiol) group that is responsible for several unique side effects not shared by other ACE inhibitors:
- Taste disturbance (dysgeusia) - metallic or loss of taste
- Skin rash
- Leukopenia (neutropenia)
- Glomerulopathy with proteinuria
The newer ACE inhibitors lack this sulfhydryl group, so their side effect burden is lower. (Washington Manual of Medical Therapeutics; Brenner & Rector's The Kidney)
Tolerability Comparison of Commonly Used Agents
| Drug | Tolerability Notes |
|---|---|
| Captopril | Worst tolerated - sulfhydryl-related rash, dysgeusia, leukopenia; requires TID dosing which adds to adherence issues |
| Enalapril | Better tolerated than captopril; prodrug (requires hepatic conversion); BID dosing |
| Lisinopril | Generally considered one of the best tolerated - once-daily dosing, not a prodrug (no hepatic conversion needed), prolonged half-life, predictable pharmacokinetics; renally cleared (useful in liver disease) |
| Ramipril | Very well tolerated; once or twice daily; extensively studied (HOPE trial); in the ONTARGET trial, only 4.2% discontinued due to cough - a relatively low discontinuation rate |
| Perindopril | Also well tolerated; once daily; extensive European evidence base |
| Fosinopril | Dual hepatic/renal elimination - best tolerated in renal impairment (less dose adjustment needed) |
(Barash Clinical Anesthesia 9e; Brenner & Rector's The Kidney)
The Universal Side Effect: Cough
The one side effect that all ACE inhibitors share equally is dry cough (bradykinin accumulation) - up to 20% of patients. It is:
- More common in women, African Americans, Asians (particularly Hong Kong and Korean populations)
- Can occur at any time, even months after starting
- May occasionally resolve spontaneously
- Only reliably resolved by stopping the drug and switching to an ARB
No ACE inhibitor is meaningfully better than another for cough since the mechanism is class-wide.
(Brenner & Rector's The Kidney)
Practical Bottom Line
- Lisinopril - best overall convenience (once daily, no prodrug conversion, no hepatic metabolism needed) making it a top choice for adherence and predictability
- Ramipril - best tolerability evidence from large trials (HOPE, ONTARGET) with proven cardio/renoprotective outcomes
- Fosinopril - best in significant renal impairment (does not require dose reduction)
- Avoid captopril in most patients unless a specific indication exists (e.g., short-acting titration in acute settings, or its use in cystinuria)
If any ACE inhibitor causes intolerable cough or angioedema, switch to an ARB rather than trying another ACE inhibitor - the class effect means switching within the class will not solve these problems.
Why prodrug is bad
Finding Sources
Reading File
Finding Sources
Great question - and the short answer is: prodrugs aren't inherently bad, but they have specific failure points that matter clinically.
Why Prodrug Status is a Concern (Not Inherently "Bad")
What a Prodrug Means for ACE Inhibitors
Most ACE inhibitors (enalapril, ramipril, quinapril, perindopril, fosinopril, trandolapril, etc.) are esterified prodrugs - they are pharmacologically inactive when swallowed and must be hydrolyzed by hepatic esterases into their active diacid form (e.g., enalapril → enalaprilat) before they work.
Captopril and lisinopril are the exceptions - they are administered as active drugs and do not require hepatic conversion. (Lippincott Illustrated Reviews Pharmacology)
Where Prodrugs Cause Problems
1. Hepatic Impairment (Most Important Concern)
If the liver is failing (cirrhosis, acute liver failure, severe hepatic dysfunction), the esterase conversion is impaired:
- The prodrug accumulates in the blood
- Active metabolite is underproduced
- The drug becomes unpredictable or ineffective
This is why captopril and lisinopril are preferred in patients with significant liver disease - they bypass hepatic activation entirely.
2. Delayed Onset of Action
A prodrug must first be absorbed, then travel to the liver, be converted, and then circulate to the target. This adds a pharmacokinetic step and slightly delays the peak effect compared to an active drug. For most chronic dosing this is irrelevant, but in acute settings (hypertensive urgency, acute heart failure), an active drug acts more predictably.
3. Inter-individual Variability
Hepatic esterase activity varies between people due to:
- Genetic polymorphisms
- Age (elderly often have reduced hepatic function)
- Drug interactions (other hepatically metabolized drugs)
- Concomitant liver disease
This means the same prodrug dose can produce variable plasma levels of the active drug between patients.
4. Not Actually a Disadvantage in Healthy Patients
In patients with normal liver function (the majority), prodrug status is not a problem at all. In fact, esterification was a deliberate pharmaceutical strategy to:
- Improve oral bioavailability (the active diacid forms have poor gut absorption; esterification makes them lipophilic and better absorbed)
- Achieve a smoother, longer-lasting effect
- Allow once-daily dosing for many agents
For example, captopril (active drug) needs to be given 3 times daily partly because of its short half-life, while enalapril (prodrug) is given twice daily and ramipril/lisinopril once daily - a practical win.
Summary Table
| Feature | Prodrug (e.g., enalapril, ramipril) | Active Drug (lisinopril, captopril) |
|---|---|---|
| Requires hepatic conversion | Yes | No |
| Works in liver failure | Unreliable | Reliable |
| Oral bioavailability | Better (by design) | Variable (lisinopril good; captopril moderate) |
| Dosing frequency | Usually once/twice daily | Captopril TID; lisinopril once daily |
| Onset | Slightly delayed | Faster |
| Variability | More inter-individual variation | More predictable |
Bottom Line
The prodrug design of most ACE inhibitors is a pharmacokinetic trade-off, not a flaw. The main clinical scenario where it genuinely matters is liver failure - in which case lisinopril is the go-to ACE inhibitor since it is the only one that is both an active drug and has convenient once-daily dosing.
This is a shared conversation. Sign in to Orris to start your own chat.